<DOC>
	<DOCNO>NCT02358499</DOCNO>
	<brief_summary>The main goal study see body break antifungal drug name posaconazole child certain cancer , blood disorder , transplantation bone marrow similar blood cell . This study also help u learn whether child 's age , genetics , disease affect well body break posaconazole .</brief_summary>
	<brief_title>Genetic Variation Variability Posaconazole Pharmacokinetics Children</brief_title>
	<detailed_description>The purpose research study see body break posaconazole , limited data child . Posaconazole injection approve FDA prevention treatment certain fungal infection adult patient . In child , however , n't data best give posaconazole whether dose personalize individual child . This study aim determine pharmacokinetics posaconazole aqueous solution injection child age 2 17 year explore difference drug exposure age , genetics , disease state . Children receive single dose posaconazole injection blood level posaconazole check . The study also check safety give posaconazole .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>1 . Age 2 year 18 year 2 . Weight â‰¥10 kg 3 . Diagnosis follow : malignancy ( e.g. , acute myelogenous leukemia [ AML ] , acute lymphoblastic leukemia [ ALL ] , lymphoma , solid tumor malignancy ) , hemophagocytic syndrome , bone marrow failure syndrome ( e.g. , myelodysplastic syndrome aplastic anemia ) , hematopoietic stem cell transplantation ( HSCT ) recipient , primary immune deficiency neutrophil Tcell defect ( e.g. , chronic granulomatous disease , hyper IgE syndrome , severe combine immune deficiency ) . 1 . A female subject must pregnant , intend become pregnant study , breastfeed 2 . A subject must receive follow medication within 24 hour posaconazole infusion ( accord standard care protocol ) : sirolimus , everolimus , pimozide , quinine , HMGCoA reductase inhibitor primarily metabolize CYP3A4 ( e.g. , atorvastatin , lovastatin , simvastatin ) , ergot alkaloid ( ergotamine , dihydroergotamine ) , methadone , astemizole , cisapride , halofantrine , salmeterol , vincristine . Potential enrollee screen additional concomitant medication pose serious safety concern give concomitantly posaconazole . Any medication exclusion criterion , unless concomitant medication may hold 24 hour posaconazole infusion accord standard care protocols 3 . A subject must receive follow medication concomitant ( within 5 halflives prior ) posaconazole infusion PK sampling : rifampin , rifapentine , rifabutin , phenytoin , efavirenz , fosamprenavir , cimetidine . Potential enrollee screen additional concomitant medication may affect posaconazole metabolism . Any medication exclusion criterion , unless concomitant medication may hold 5 halflives prior posaconazole infusion PK sample 4 . A subject must moderate severe liver dysfunction ( except chronic case judge P.I . ) Baseline , define : A subject must moderate severe liver dysfunction Baseline , define : Aspartate aminotransferase ( AST ) &gt; 5 time upper limit normal ( ULN ) , OR Alanine aminotransferase ( ALT ) &gt; 5 time ULN , OR Serum total bilirubin &gt; 2.5 time ULN , OR 5 . A subject must electrocardiogram ( ECG ) prolong age , sexadjusted QTc interval . 6 . A subject must history dysrhythmia . 7 . A subject must creatinine clearance level ( measure calculate ) 50 mL/min/1.73 m2 . 8 . A subject must history Type 1 hypersensitivity idiosyncratic reaction azole agent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>triazoles</keyword>
	<keyword>fungi</keyword>
	<keyword>transplantation , hematopoietic stem cell</keyword>
	<keyword>leukemia</keyword>
	<keyword>pediatrics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bone marrow failure syndrome</keyword>
</DOC>